4.99
+2.04%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cryo-Cell International
From its filings with the US Securities and Exchange Commission
Cryo-Cell International is based in Oldsmar, Florida and is incorporated in Delaware. Its shares trade on NYSE under the ticker CCEL. The SEC classifies its business as misc health & allied services, nec. In the fiscal year to 30 November 2025, it reported revenue of $31.6m and a net loss of $2.4m. At that date it held total assets of $61.7m and shareholders' equity of −$18.6m.
Cryo-Cell International, Inc. (the “Company” or “Cryo-Cell”) is a Delaware corporation that was incorporated in 1989. The Company is organized in three reportable segments; 1.) cellular processing and cryogenic storage for family use, with a current focus on the collection and preservation of umbilical cord blood and tissue stem cells, 2.) the manufacture of PrepaCyte® CB Processing System (“PrepaCyte CB”) units, the processing technology used to process umbilical cord blood stem cells, and 3.) cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company, in combination with its global affiliates, currently stores over 250,000 cord blood and cord tissue specimens worldwide for the exclusive benefit of newborn babies and possibly other members of their families. Founded in 1989, the Company was the world’s first private cord blood bank to separate and store stem cells in 1992. The Company's U.S.-based business operations, including the processing and storage of specimens, are handled from its headquarters facility in Oldsmar, Florida. The specimens are primarily stored in commercially available cryogenic storage units at the Company's technologically and operationally advanced facility in Durham, NC.
Quoted from its 10-K, filed 27 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 4 Apr 1994
- Employees
- 72
- Website
- cryo-cell.com ↗
- Head office
- 700 BROOKER CREEK BLVD, OLDSMAR, FL, 34677
- Incorporated in
- DE
- Classification
- Services-Misc Health & Allied Services, NEC
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. David PortnoyChairman of the Board, Co-Chief Executive Officer, since 2011$1.9m
- Mr. Mark PortnoyCo-Chief Executive Officer, Director, since 2011$1.2m
- Ms. Jill TaymansChief Financial Officer, Vice President - Finance$307,304
- Mr. Oleg MikulinskyChief Information Officer$432,280
- Dr. Joanne KurtzbergMedical Director
- Mr. Harold BergerIndependent Director$72,342
- Mr. Daniel MizrahiIndependent Director$72,342
- Ms. Irene SmithExecutive Assistant / Office Manager, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cryo-Cell International Inc has a strong reputation in the stem cell industry, recognized for its expertise and quality services. The company has a well-established customer base and a robust network of healthcare professionals. Its advanced technology and scientific advancements give it a competitive edge. Cryo-Cell also benefits from a solid financial position and strong revenue growth.
Weaknesses
- Despite its strengths, Cryo-Cell International Inc faces certain weaknesses. The company's marketing efforts could be improved to enhance brand awareness and reach a broader audience. The high cost associated with the company's services may limit market penetration. Additionally, Cryo-Cell is exposed to potential legal and regulatory risks in the evolving field of stem cell research.
Opportunities
- Cryo-Cell International Inc operates in an industry with significant growth potential. Advancements in stem cell research and therapies open doors for expansion and new market opportunities. The company can leverage its expertise to diversify its service offerings, such as exploring partnerships in regenerative medicine or geographical expansion. Cryo-Cell can also capitalize on the increasing demand for personalized medicine and genetic testing.
Threats
- Cryo-Cell International Inc faces several threats that require careful consideration. Intense competition within the stem cell industry could potentially impact market share. The regulatory environment surrounding stem cell research and therapies remains subject to change, which may pose challenges for Cryo-Cell's operations. Economic uncertainties and fluctuations in healthcare policies or insurance coverage also present risks to the company's financial stability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.